

Anti-Adrenomedullin (human)
Mouse monoclonal antibody

Subclass: IgG1/k
Clone: 1D2C2C10

CAT. NO.

ABS 027-01

SPECIFICITY	ABS 027-01 binds human adrenomedullin and shows no cross-reaction with CGRP.
IMMUNOGEN	Synthetic human adrenomedullin 1-52
TESTED APPLICATIONS	ELISA, WB
SPECIES REACTIVITY (POSITIVE)	Human
SPECIES REACTIVITY (NEGATIVE)	Not determined
EPITOPE SPECIFICITY	The epitope of ABS 027-01 lies within residues 22-52.

PRESENTATION

Content:	Available in 400 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Preparation:	Protein-A purified
Form:	Liquid
Solvent:	0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Storage:	4-8°C without exposure to light. No precautions necessary during handling.

APPLICATION

ELISA: The binding of ABS 027-01 to this coat is not inhibited by full length adrenomedullin in solution up to a concentration of 1 µmol/L, but is inhibited by adrenomedullin (22-52) in solution.
WB: ABS 027-01 can be used in Western blotting.

TARGET

Human adrenomedullin is a 52 amino acid peptide (MW 6029) with the physiological effect of lowering blood pressure through vasodilatation, an effect it shares with calcitonin gene-related peptide (CGRP) and vasoactive intestinal peptide (VIP). In addition, adrenomedullin has other cardiovascular effects including growth and development of both cardiovascular tissues and bone, and has effects in the central nervous system connected with the regulation of fluid balance.

REFERENCES

CONDITIONS

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.